<DOC>
	<DOCNO>NCT02472886</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fix dose combination ( FDC ) without ribavirin ( RBV ) adults chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Safety Efficacy Ledipasvir/Sofosbuvir Adults With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Participants fail treatment Study GSUS3340119 meet relevant inclusion/exclusion criterion eligible retreatment study Chronic genotype 1 HCV infection HCV treatmentnaive HCV RNA &gt; 10,000 IU/mL screen Absence cirrhosis Screening laboratory value within define threshold Use two effective contraception method female childbearing potential sexually active male Pregnant nursing female male pregnant female partner Infection hepatitis B virus ( HBV ) Current prior history clinical hepatic decompensation Chronic use systemic immunosuppressive agent History clinically significant illness medical disorder may interfere individual 's treatment , assessment , compliance protocol For HIV1/HCV coinfected individual : Opportunistic infection within 6 month prior screen Active , serious infection ( HIV1 HCV ) require parental antibiotic , antiviral antifungal within 30 day prior baseline Treatment antiretroviral ( ARV ) regimen one list study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HCV genotype 1</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>ledipasvir</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>